<unk>  is a pharmacodiagnostic test used to determine the tumor sensitivity or resistance to drug regimens recommended for the treatment of breast cancer by the National Comprehensive Cancer Network. It is a noninvasive test performed on small amounts of tissue removed during the original surgery lumpectomy, mastectomy, or core biopsy.<unk>  was developed by CCC Diagnostics Inc., a biotechnology company established by former researchers from Johns Hopkins University.<unk>  was launched on 14 January 2010. Currently, it is the only available test for predicting treatment outcomes for anticancer chemotherapy drugs for breast cancer.
DirectHit
Clone 
Proximate
GeneRec
Sense
Independent SAGE
QTY Code
Next-generation matrix